

Stefan Boeck

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9617341/publications.pdf>

Version: 2024-02-01

86
papers

4,028
citations

145106

33
h-index

139680

61
g-index

89
all docs

89
docs citations

89
times ranked

6790
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN- γ , TNF- α and PD-1/PD-L1 in comparison to established serum tumor markers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2463-2474.	1.2	3
2	Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study. <i>ESMO Open</i> , 2022, 7, 100388.	2.0	10
3	Novel systemic treatment approaches for metastatic pancreatic cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 249-262.	1.9	12
4	Comment on: "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis". <i>Annals of Surgery</i> , 2022, 276, e1123-e1124.	2.1	2
5	The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. <i>International Journal of Cancer</i> , 2022, , .	2.3	4
6	Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	7
7	R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007 trial. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 8-18.	1.0	26
8	Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the "burden of therapy" method. <i>European Journal of Cancer</i> , 2021, 146, 95-106.	1.3	21
9	Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. <i>Clinical and Translational Oncology</i> , 2021, 23, 2394-2401.	1.2	8
10	Rituximab Treatment of Hairy Cell Leukemia in a Patient with <i>Mycobacterium kansasii</i> Infection: A Case Report. <i>Oncology Research and Treatment</i> , 2021, 44, 1-4.	0.8	0
11	Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 5732.	1.7	8
12	Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 391-399.	1.2	13
13	Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz060.	1.4	7
14	Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study. <i>British Journal of Cancer</i> , 2020, 123, 1370-1376.	2.9	10
15	Advances in cancer immunotherapy 2019 – latest trends. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 268.	3.5	401
16	Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts. <i>Clinical and Translational Oncology</i> , 2019, 21, 1108-1111.	1.2	10
17	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology</i> , The, 2018, 19, e151-e160.	5.1	51
18	Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. <i>European Journal of Cancer</i> , 2018, 95, 109-111.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant chemoradiation for esophageal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 435-443.	1.0	5
20	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 404-415.	5.5	56
21	Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the "Arbeitsgemeinschaft Internistische Onkologie". <i>European Journal of Cancer</i> , 2018, 94, 95-103.	1.3	32
22	Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2018, 155, 1625-1639.e2.	0.6	152
23	Clinical outcome of elderly patients (≥70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis. <i>Radiation Oncology</i> , 2018, 13, 93.	1.2	23
24	Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2018, 29, 2348-2355.	0.6	113
25	POLE gene hotspot mutations in advanced pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2161-2166.	1.2	15
26	Oligometastatic Disease in Pancreatic Cancer - How to Proceed. <i>Visceral Medicine</i> , 2017, 33, 36-41.	0.5	34
27	Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 1462-1469.	2.9	25
28	Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. <i>Oncolmmunology</i> , 2017, 6, e1310358.	2.1	111
29	Improving post-surgical management of resected pancreatic cancer. <i>Lancet, The</i> , 2017, 390, 847-848.	6.3	6
30	Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1775-1783.	0.9	9
31	Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research. <i>BMC Cancer</i> , 2017, 17, 374.	1.1	1
32	Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer – A retrospective cohort study. <i>Thrombosis Research</i> , 2017, 157, 9-15.	0.8	49
33	Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course. <i>Annals of Oncology</i> , 2017, 28, 438-439.	0.6	4
34	The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1094.	1.8	20
35	Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash. <i>Oncotarget</i> , 2017, 8, 35193-35204.	0.8	10
36	Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 593-598.	0.5	58

#	ARTICLE	IF	CITATIONS
37	Safety of palliative chemotherapy in advanced pancreatic cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 947-954.	1.0	8
38	Dosing to rash? â€œ The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. <i>European Journal of Cancer</i> , 2016, 55, 131-139.	1.3	19
39	Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2585-2591.	1.2	26
40	Projections of cancer incidence and cancerâ€™related deaths in Germany by 2020 and 2030. <i>Cancer Medicine</i> , 2016, 5, 2649-2656.	1.3	195
41	Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials. <i>British Journal of Cancer</i> , 2016, 115, 1520-1529.	2.9	20
42	Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study. <i>International Journal of Surgery</i> , 2016, 28, 118-125.	1.1	46
43	Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 355-360.	2.8	22
44	Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. <i>Surgery</i> , 2015, 158, 151-161.	1.0	54
45	Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. <i>Tumor Biology</i> , 2015, 36, 2631-2640.	0.8	12
46	Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: A subgroup analysis from AIO-PK0104. <i>Acta Oncologica</i> , 2015, 54, 993-1000.	0.8	7
47	High-throughput screening identified inherited genetic variations in the EGFR pathway contributing to skin toxicity of EGFR inhibitors. <i>Pharmacogenomics</i> , 2015, 16, 1605-1619.	0.6	7
48	Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult. <i>British Journal of Cancer</i> , 2014, 111, 1675-1676.	2.9	3
49	Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors. <i>Oncology</i> , 2014, 86, 24-32.	0.9	45
50	Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2014, 25, 1095-1101.	0.7	14
51	pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. <i>BMC Cancer</i> , 2014, 14, 624.	1.1	29
52	ALK expression is absent in pancreatic ductal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1625-1628.	1.2	5
53	Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. <i>European Journal of Cancer</i> , 2014, 50, 1855-1863.	1.3	46
54	Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. <i>European Journal of Cancer</i> , 2014, 50, 1891-1899.	1.3	31

#	ARTICLE	IF	CITATIONS
55	Translational Research in Pancreatic Cancer. <i>Pancreas</i> , 2014, 43, 150-152.	0.5	5
56	Translational research in pancreatic ductal adenocarcinoma: Current evidence and future concepts. <i>World Journal of Gastroenterology</i> , 2014, 20, 10769.	1.4	20
57	Long-term progression-free survival in a metastatic pancreatic cancer patient treated with first-line nab-paclitaxel and gemcitabine. <i>In Vivo</i> , 2014, 28, 1189-92.	0.6	3
58	Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 681-689.	1.2	125
59	KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. <i>Journal of Gastroenterology</i> , 2013, 48, 544-548.	2.3	66
60	Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNase in patients with advanced pancreatic cancer undergoing chemotherapy. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	2.3	48
61	Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. <i>Journal of Clinical Oncology</i> , 2013, 31, 4453-4461.	0.8	147
62	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO-PK0104). <i>Gut</i> , 2013, 62, 751-759.	6.1	105
63	Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. <i>Annals of Oncology</i> , 2013, 24, 2484-2492.	0.6	102
64	EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. <i>British Journal of Cancer</i> , 2013, 108, 469-476.	2.9	84
65	Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2013, 108, 1684-1694.	2.9	48
66	Systemic treatment of advanced pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 843-853.	3.4	108
67	External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy. <i>Pancreas</i> , 2012, 41, 738-744.	0.5	1
68	Surgical treatment concepts for patients with pancreatic cancer in Germany" results from a national survey conducted among members of the "Chirurgische Arbeitsgemeinschaft Onkologie" (CAO) and the "Arbeitsgemeinschaft Internistische Onkologie" (AIO) of the Germany Cancer Society (DKG). <i>Langenbeck's Archives of Surgery</i> , 2011, 396, 223-229.	0.8	15
69	Erlotinib 150mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO). <i>Anti-Cancer Drugs</i> , 2010, 21, 94-100.	0.7	28
70	Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. <i>Tumor Biology</i> , 2010, 31, 351-357.	0.8	46
71	Reply to: The definition of locally advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2010, 102, 1308-1308.	2.9	0
72	Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 986-994.	3.2	41

#	ARTICLE	IF	CITATIONS
73	Current Oncological Treatment of Patients with Pancreatic Cancer in Germany: Results from a National Survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. <i>Oncology</i> , 2009, 77, 40-48.	0.9	20
74	Cisplatin-Based Chemotherapy for Pulmonary Metastasized Germ Cell Tumors of the Testis – Be Aware of Acute Respiratory Distress Syndrome. <i>Oncology Research and Treatment</i> , 2009, 32, 125-128.	0.8	2
75	Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. <i>Cancer Treatment Reviews</i> , 2009, 35, 262-271.	3.4	184
76	Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. <i>BMC Cancer</i> , 2008, 8, 82.	1.1	377
77	Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2008, 19, 340-347.	0.6	70
78	The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. <i>Future Oncology</i> , 2008, 4, 41-50.	1.1	18
79	Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer. <i>Oncology</i> , 2007, 73, 221-227.	0.9	46
80	Assessing Prognosis in Metastatic Pancreatic Cancer by the Serum Tumor Marker CA 19-9: Pretreatment Levels or Kinetics during Chemotherapy?. <i>Oncology Research and Treatment</i> , 2007, 30, 39-42.	0.8	11
81	The Role of Adjuvant Chemotherapy for Patients with Resected Pancreatic Cancer: Systematic Review of Randomized Controlled Trials and Meta-Analysis. <i>Oncology</i> , 2007, 72, 314-321.	0.9	75
82	Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. <i>Annals of Oncology</i> , 2007, 18, 745-751.	0.6	61
83	Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2007, 18, 1109-1111.	0.7	18
84	Importance of performance status for treatment outcome in advanced pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2007, 13, 224.	1.4	69
85	Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. <i>Bone Marrow Transplantation</i> , 2006, 37, 57-64.	1.3	20
86	Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer. <i>Oncology</i> , 2006, 70, 255-264.	0.9	154